News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche Holding AG (RHHBF.PK) First-Half Profit Climbs 10% on Cancer Medicines


7/25/2013 7:22:18 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Roche Holding AG’s (ROG) first-half profit climbed 10 percent as new breast-tumor drugs Kadcyla and Perjeta showed signs of being able to fuel growth as the Swiss drugmaker prepares for lower-priced copies of its main cancer medicines. Earnings excluding some items, which the company calls core net income, climbed to 6.65 billion Swiss francs ($7.1 billion), Basel-based Roche said in a statement today. Earnings per share on that basis were 7.58 francs, beating the 7.45-franc average of 12 analysts’ estimates compiled by Bloomberg.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Market Watch
Read at Washington Post
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES